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• ESR1mutations lead to constitutive activation of ERα and resistance to aromatase inhibitors.
• A subset of gynecologic malignancies, particularly those with endometrioid histology, harbor ESR1 mutations.
• ESR1mutations may arise in the setting of treatment with AIs, or may be present in the initial tumor.
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Available online xxxxObjective. Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malig-
nancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic re-
sistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this studywas to evaluate the
frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies.
Methods. DNA from FFPE tumor tissue obtained during routine clinical care for 9645 gynecologic malignan-
cies (ovary, fallopian tube, uterus, cervix, vagina, vulvar, and placenta)was analyzed for all classes of genomic al-
terations (base substitutions (muts), insertions, deletions, rearrangements, and amplifications) in ESR1 by hybrid
capture next generation sequencing. A subset of alterations was characterized in laboratory-based transcription
assays for response to endocrine therapies.
Results. A total of 295 ESR1 genomic alterations were identified in 285 (3.0%) cases.mutESR1were present in
86 (0.9%) cases and were more common in uterine compared to other cancers (2.0% vs b1%, respectively p b
0.001). mutESR1 were enriched in carcinomas with endometrioid versus serous histology (4.4% vs 0.2% respec-
tively, p b 0.0001 in uterine and 3.5% vs 0.3% respectively, p=0.0004 in ovarian carcinomas). In three of four pa-
tients with serial sampling, mutESR1 emerged under the selective pressure of AI therapy. Despite decreased
potency of estrogen receptor (ER) antagonists in transcriptional assays, clinical benefit was observed following
treatment with selective ER-targeted therapy, in one case lasting N48 months.
Conclusions.While the prevalence of ESR1mutations in gynecologic malignancies is low, there are significant
clinical implications useful in guiding therapeutic approaches for these cancers.
© 2019 Elsevier Inc. All rights reserved.el Cancer Center, 201 N. Broadway, Baltimore, MD 21287, United States of America.
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Table 1
Types and frequency (%) of ESR1 alterations identified in gynecologicmalignancies by pri-
mary site.











Total 295 (3.1)b 120 (2.1) 160 (5.2) 9 (1.2) 6 (2.8)
Amplification 80 (0.8) 45 (0.8) 34 (1.1) 1 (0.1) –
Deletion 1 (b0.1) – 1 (b0.1) – –
Fusion 2 (b0.1) 1 (b0.1) – – 1 (0.5)
Rearrangements 18 (0.2) 9 (0.2) 9 (0.3) – –
Total substitution
variants
194 (2.0) 65 (1.2) 116 (3.7) 8 (1.1) 5 (2.3)
Codon 536–538 75 (0.8) 18c (0.3) 56c (1.8) 1 (0.1) –
Other activating Mut 12 (0.1) 3 (0.0) 7 (0.2) – 2 (0.9)
“–”: none present. Abbreviations: FT: fallopian tube, Mut: mutation.
a No ESR1 alterations were identified among 14 cases of placental cancers included in
total number of cases assessed.
b Includes 10 cases with 2 alterations each.
c 1 ovarian case and 2 uterine cases had 2 codon 536–538 mutations each.
Table 2







Cervix 720 1 (0.1)
Clear cell 15 1 (6.7) – 1
Ovary/FT 5594 21 (0.4)
Carcinoma NOS 1079 4 (0.4) 2 2
Endometrioid 144 5 (3.5) 2 3
Serous 3502 12 (0.3) 12 –
Uterus 3101 63 (2.0)
Carcinoma NOS 1063 27 (2.5) 10 17
Endometrioid 548 24 (4.4) 10 14
Clear cell 78 1 (1.3) – 1
Papillary serous 446 1 (0.2) – 1
Carcinosarcoma 303 4 (1.3) 4 –
Leiomyosarcoma 421 3 (0.7) 2 1
ESS 103 3 (3.0) 3 –
Vulva/vagina 216 2 (0.9)
SCC 134 1 (0.7) – 1
Adenocarcinoma 32 1 (3.1) – 1
Total 9645a 86 (0.9) 45 (52.3) 41 (47.7)
“–”: none detected. Abbreviations: FT: fallopian tube, ESS: endometrial stromal sarcoma,
SCC: squamous cell carcinoma, NOS: not otherwise specified.
a No ESR1 alterations were identified among 14 cases of placental cancers included in
total number of cases assessed.
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Gynecologic malignancies commonly express estrogen receptor
(ER) and/or progesterone receptor (PR) and endocrine therapy is
often considered as treatment for advanced, potentially hormone-
sensitive gynecologic cancers, especially low-grade endometrial and
ovarian tumors. Endocrine therapy blocks ER signaling through a variety
of strategies, most commonly estrogen-deprivation, as with aromatase
inhibitors (AI), or direct-antagonism of ER through selective ER-
modulators (SERMs) or -degraders (SERDs).
Failure of endocrine therapy occurs through intrinsic or acquired re-
sistance mechanisms. Mutations in ERα (encoded by ESR1) are a mech-
anism of resistance to endocrine therapy commonly observed in
metastatic breast cancer. These mutations occur predominantly in the
ligand-binding domain (LBD) of the receptor and result in constitutive
activation of ERα in the absence of estrogen. Activating ESR1mutations
(mutESR1) most frequently occur in a hotspot region encompassing
amino acids 536–538 within the ERα LBD [1,2], with a smaller number
occurring at other LBD sites, namely E380, V422, S463, and L469 [3–5].
In breast cancer,mutESR1 arise in 25–50% of patients who receive endo-
crine therapy, especially AIs, but are relatively rare (3%) in primary tu-
mors [1,4,6–8]. Thus, mutESR1 are primarily an acquired resistance
pathway to endocrine therapy thatmay also account for rare cases of in-
trinsic resistance.
ESR1 amplification has also been suggested as a mechanism of resis-
tance to endocrine therapy resulting in worse outcomes [9,10]. ESR1
amplification is reported in early pre-cursor lesions of endometrial can-
cer [11–13]. However, the clinical impact of ESR1 amplifications is con-
troversial and detection methods may result in overcalling of this
genomic alteration [14].
A study evaluating ERα as a predictive biomarker in endometrioid
endometrial cancer identified 19 cases of mutESR1 in 1034 samples
(1.8%) [15]. This study focused solely on mutations arising in codons
536–538, was limited to endometrioid endometrial cancers, and did
not provide clinical information regarding prior endocrine therapy or
response to therapy.
The purpose of the current study was to quantify the frequency of
ESR1 genomic alterations, includingmutESR1, identified by comprehen-
sive genomic profiling in gynecologic malignancies. We present our
clinical experience treating tumors with both de novo and acquired
mutESR1. The effect of selected SERMs and SERDs on the transcriptional
activity of individual mutESR1 was examined.
2. Results
2.1. ESR1 genomic profiles in gynecologic malignancies
Of the 9645 clinical samples from gynecologic malignancies evalu-
ated with CGP in this study, 285 (3%) samples contained a total of 295
ESR1 alterations, including substitutions, amplification, and rearrange-
ments. Ten cases exhibited two separate alterations each. The types
and frequency of alterations by site of disease origin are listed in
Table 1. Substitutionswere themost common ESR1 alteration identified
(194/295, 66%), with 44% (86/194) of those occurring in ESR1 codons
expected to result in ERα constitutive activity. Of the activating variants,
alterations in codons 536–538 were most common accounting for 25%
(75/295) of all ESR1 alterations and occurring in 0.8% (75/9645) of
cases. Another 12 cases (0.1%) contained V422del, S463P, or L469muta-
tions. ESR1 amplifications were the next most common genomic alter-
ation identified (80/295, 27%) and were present in 0.8% of cases.
Median ESR1 copy number in amplified cases was 8 (range 6–38).
ESR1 rearrangements were present in 0.2% of cases (Table S1).
Types and frequency of mutESR1 by histologic subtype are listed in
Table 2. mutESR1 were more common in uterine cancers (63/3101,
2%) compared to other primary sites (24/6530, b1%, p b 0.0001).
mutESR1 were enriched in carcinomas with endometrioid histology:Please cite this article as: S.L. Gaillard, K.J. Andreano, L.M. Gay, et al., Constit
response to estrogen-receptor directed therapies..., Gynecologic Oncology4.4% (24/548) in uterine endometrioid vs 0.2% (1/446) in uterine serous
carcinomas (p b 0.0001) and 3.5% (5/144) in ovarian endometrioid
compared to 0.3% (12/3502) in ovarian serous carcinomas (p =
0.0004). Two uterine endometrioid carcinomas exhibited the following
co-occurring ESR1 mutations: Y537N with Y537S, and L536H with
Y537C, respectively. An ovarian serous carcinoma exhibited both ESR1
Y537S and D538G. Grade was not available for any of the uterine cases
and absent for 89% of the ovarian cases, thus an assessment based on
grade could not be performed. Uterine endometrial stromal sarcomas
(ESS) had a proportionally higher frequency of mutESR1 than uterine
leiomyosarcomas (LMS) [3/103 (3%) vs. 3/421 (0.7%), respectively],
though this did not reach statistical significance (p = 0.09).
To further examine the prevalence ofmutESR1 in human ovarian and
endometrial cancers, publically available databases were explored
[16–21] using the cBioPortal [22,23] and COSMIC [24]. In total 41 gyne-
cologic malignancies withmutESR1were identified (Table S2). The ma-
jority (37/41, 90%) occurred in uterine tumors including 2 cases of
endometrial stromal sarcoma. No cases were identified in the cervical
cancer TCGA database or the ovarian cancer TCGAdatabase,which com-
prises exclusively high-grade serous cancer cases. One endometrial case
had 2mutESR1 alleles (V422del and Y537H). Interestingly, the majority
of themutESR1 occurred in endometrioid tumors (34/41, 83%). An addi-
tional uterine endometrioid case was identified with an ESR1 P535Hutively active ESR1mutations in gynecologicmalignancies and clinical
, https://doi.org/10.1016/j.ygyno.2019.04.010
3S.L. Gaillard et al. / Gynecologic Oncology xxx (xxxx) xxxmutation. This mutation has not been functionally characterized and it
was not included in the analyses.
The overall frequency of cases with mutESR1 in the publically avail-
able databases was similar to that seen in the CGP dataset. In the
AACR Project GENIE databases, mutESR1 were present in 2.3% (32/
1363) of uterine endometrial cancers, 0.1% (2/1733) of ovarian cancers,
0.4% (1/279) of cervical cancers, and 0.9% (2/234) of uterine sarcomas.
Similarly,mutESR1were enriched in endometrioid endometrial cancers
[30/654 (4.6%) endometrioid vs 0/244 serous, p = 0.0001] and
endometrioid ovarian cancers [2/70 (2.9%) endometrioid vs. 0/838
high-grade serous, p= 0.006].mutESR1 was enriched in ESS compared
to LMS (2/16 vs 0/129, respectively, p = 0.012) in the AACR Project
GENIE uterine sarcoma dataset. Of the 248 cases with mutation data in
the TCGA uterine corpus dataset, 5 (2.0%) contained mutESR1, all with
endometrioid histology; however the comparison between
endometrioid and serous histology did not show a statistically signifi-
cant difference [5/200 (2.5%) endometrioid vs 0/44 serous, p = 0.59].
In sum, combining our CGP dataset and the publically available
datasets, 125 gynecologic malignancies with 129 individual mutESR1
were identified. Variants most commonly occurred in the known
hotspot region, with 29/129 (22.5%) in codon 536, 59/129 (45.7%) in
codon 537, and 24/129 (18.6%) in codon 538. Fig. 1 presents a schematic
overview and frequency distribution of the mutESR1 identified. Y537S
(42/129, 32.6%) and D538G (24/129, 18.6%) were themost common in-
dividual mutESR1 identified.
2.2. Clinical relevance of mutESR1 in gynecologic malignancies and re-
sponse to treatment
Detailed clinical information was available for 8 patients with
mutESR1. Fig. 2 and Table 3 illustrate the clinical course for patients
identified withmutESR1 tumors. In 5 of 8 cases,mutESR1was identifiedB
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Fig. 1. Schematic overview ofmutESR1 identified in gynecologicmalignancies. (A) Distribution o
binding domain, LBD: ligand binding domain.
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gence of mutESR1 (Patients A and G) or an increase in allelic frequency
(Patient D). Patient D had two exposures to AI: one of short duration
(1 month) and a subsequent exposure lasting 7 months. Because no
pre-AI sample is available, when the mutESR1 first evolved cannot be
determined. However, the allelic frequency of ESR1 Y537S was in-
creased after the second exposure (37% post-7-months vs 4% post-1-
month, 9.25-fold increase) compared to KRAS (40% post-7 months vs
23% post-1 month, 1.74-fold increase).
Table S3 outlines the clinical benefit duration (CBD) achieved with
SERM/SERD therapy compared to the immediate antecedent therapy.
Of the 8 cases, 6 experienced a greater duration of benefit with ER-
directed therapy than chemotherapy. In some cases, ER-directed ther-
apy led to extended benefit. In particular, a 58-year-oldwoman (Patient
C) with Stage IIIC primary peritoneal low-grade serous carcinoma had
no tumor response to neoadjuvant chemotherapy. She underwent
cytoreductive surgery and CGP revealed an ESR1 Y537N mutation. The
patient had no prior history of endocrine therapy. Immunohistochemis-
try (IHC) showed this mutation was associated with high ERα expres-
sion (Fig. 2B). Given the concern for intrinsic resistance to AI therapy
conferred by the mutation, treatment with fulvestrant was started and
within 4 months she experienced a major CA125 biochemical response
(Fig. 2B). She has had prolonged clinical benefit of N4 years with mini-
mal residual disease based on radiologic imaging. In other cases,
switching therapy to an alternate SERM or SERD after progression on
the initial ER-targeted therapy also provided clinical benefit (Patients
A and B). Patient A experienced a combined total of 20 months CBD
with tamoxifen followed by fulvestrant compared to 2.5 months CBD
with the antecedent chemotherapy. Therefore, despite the presence of
an activating ESR1 mutation, therapy with ER-targeting agents can be
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Fig. 2. Clinical relevance ofmutESR1 in gynecologic malignancy. A. Clinical course of patients identifiedwith gynecologic malignancies harboringmutESR1. Eight individual patients (A–H)
withmutESR1were identified. Each box or wide arrow delineates a treatment received colored according to the legend and the width reflects relative duration of therapy. A wide arrow
represents ongoing therapy. Hashed boxes/arrows reflect combined therapy. The triangle reflectswhen the sample evaluated by CGPwas procured. Percentages reflect allelic frequency of
the mutation within the sample. B. (top) Expression of ERα in tumor harboring ESR1 Y537N. H&E stain (left) and ERα by immunohistochemistry (right). (bottom) CA125 response after
initiation of fulvestrant (arrow). Upper limit of normal of the CA125 test (dashed horizontal line).
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cancer cells
In breast cancer cell lines, mutESR1 exhibit decreased sensitivity to
tamoxifen and fulvestrant. We evaluated the transcriptional activity in
response to SERMs or SERDs of the most common mutESR1 identified
in our series using a reconstituted ERE-luciferase reporter assay in
CAOV2 ovarian carcinoma cells. ERα constructs were generated con-
taining 3 different amino acid substitutions at position 537 (Y537C,
Y537N, Y537S) and 1 at position 538 (D538G). The wild-type ERα re-
ceptor (WT) was only activated in the presence of 17-beta estradiol
(E2). Each of the mutants exhibited substantial constitutive activity in
the absence of E2 when compared to the activity of ERα WT (Fig. 3A).
The constitutive activity of each of the receptors was similar to themax-
imally E2-stimulated activity of the WT receptor, with the exceptionTable 3
Clinical characteristics of patients identified with mutESR1 gynecologic malignancies.
Patient Age Disease site (histology) CGP sample (ESR1 mutation, %
allelic frequencya)
A 24 Ovary (LG serous) PCS (none)
SCS (Y537S)
B 35 Synchronous endometrial and
ovary (LG endometrioid)
PCS (Y537S)
C 58 Primary peritoneal (LG serous) ICS (Y537N)
D 43 Ovary (LG serous) SCS (Y537S, 4%)
Biopsy after 2nd AI (Y537S, 37%)
E 59 Ovary (HG endometrioid) SCS (Y537S)
F 40 Ovary (HG serous) SCS (none)
Biopsy after multiple chemo (D538G)
G 59 Ovary (LG → HG serous) PCS (none)
Biopsy of HG serous recurrence (Y537S)
H 59 Endometrial (LG endometrioid) Biopsy following AI (D539G)
a Percent allelic frequency reported if known. LG: low-grade, HG: high-grade, PCS: primary cy
(after neoadjuavant chemotherapy), chemo: chemotherapy.
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(134% compared to WT receptor, p = 0.0137).
The ability of clinically available SERMs [tamoxifen, tested in this study
as its active metabolite, 4-hydroxytamoxifen (4OHT); raloxifene;
bazedoxifene; and lasofoxifene] and SERDs [fulvestrant (ICI) and
GW7604] to inhibit ERα mutant transcriptional activity was evaluated
in ovarian cancer cells. In the CAOV2 ovarian cancer cell model, each of
the drugswas able to effectively inhibitmutant transcriptional activity, al-
beit with reduced potency when compared to the WT receptor. Fig. 3B
and C are tabular and graphical presentations of the inhibitory concentra-
tions required to reduce transcriptional activity by 50% and 90% (IC50 and
IC90, respectively). Differences in potency between the WT receptor and
individualmutations varied considerably bydrug (Table S4). For example,
the 4OHT IC50 required for Y537C is 9× higher than forWT, while the ICI












KRAS (23%) Yes (1 month prior to SCS) No
KRAS (40%) Yes (7 mths after SCS)
APC Yes (12 mths) Yes
BRCA1, TP53 No No
BRCA1, TP53
TP53, CIC Yes (30 mths) Yes
TP53, CIC
AKT1, CTNNB1, ARID1A, MLL Yes (60 mths) Yes
toreductive surgery, SCS: second cytoreductive surgery, ICS: interval cytoreductive surgery
utively active ESR1mutations in gynecologicmalignancies and clinical
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Fig. 3. ERα LBD mutations confer constitutive transcriptional activity and alter receptor sensitivity to SERMs/SERDs. A. Luciferase assay measuring transcriptional activity of the WT and
mutant receptors.WT+E2 is in the presence of 10−8Mof 17β-estradiol. B. Tabular presentation of IC50 and IC90 of each receptor:drug combination in picomolar (pM) C. Inhibition dose-
response curves for each anti-estrogen. All inhibition curves were done in the presence of 10−9 M (1 nM) 17β-estradiol. Data normalization is performed with respect to the vehicle
treatment for each individual receptor. These plots include data from five independent experiments and each value is an average of triplicates from each experiment. Dashed vertical
line in the ICI, raloxifene, bazedoxifene, and lasofoxifene graphs represents the maximal clinically achievable concentration (Cmax) for each drug respectively [25–28]. For 4OHT, the
median serum concentration is presented for 4OHT [29]. D. Comparison Cmax/IC90 ratio across mutESR1. The maximum achievable blood concentration (Cmax) for each ER antagonist
was identified in the literature [25–28] and divided by each receptor's IC90 as determined by the dose-response curves in the luciferase assays. *The median serum concentration was
used for 4OHT [29]. The values are reported on a logarithmic scale.
5S.L. Gaillard et al. / Gynecologic Oncology xxx (xxxx) xxxInterestingly, themutant receptors themselves exhibited differential
responses to the drugs (Fig. S1). The IC50 for each of the drugs on the
ERα Y537N and Y537C mutants were typically similar and within ~2
fold of each other (Table S5). In contrast, the IC50 for the ERα Y537S
and D538G mutants were more likely to be similar and frequently
higher than the IC50 for either of the other two mutants.
The IC50 and IC90 of each receptor:antagonist pair was compared in
our assays to the antagonist's reportedmaximumachievable blood con-
centration in humans (Cmax) (Table S5) [25–28]. Because the Cmax of the
tamoxifen metabolite, 4OHT, was not available, the median serum con-
centration of 4OHT measured in patients receiving tamoxifen 20 mg
daily was used [29]; the typical dose of tamoxifen used for the treat-
ment of gynecologicmalignancies is 20mg twice a day. Fig. 3D is a visual
representation of the Cmax:IC90 and shows that the concentration to
reach the IC90 is achievable with each of the antagonists for the
Y537N and Y537C mutations, while only lasofoxifene would bePlease cite this article as: S.L. Gaillard, K.J. Andreano, L.M. Gay, et al., Constit
response to estrogen-receptor directed therapies..., Gynecologic Oncologyexpected to achieve the IC90 for the D538G mutation and none reach
the IC90 for Y537S.
3. Discussion
This study demonstrated that activating mutations within the ESR1
LBD occur in gynecologic malignancies. This finding has important
treatment implications. ERα-dependent malignancies harboring these
mutations are unlikely to respond to estrogen deprivation therapies,
such as AIs, because these alterations confer constitutive transcriptional
activity to ERα. The frequency of mutESR1 in the current study is low,
only 0.9% in unselected cases. However, these mutations are enriched
in endocrine-responsive subtypes of gynecologic malignancies: specifi-
cally, the endometrioid histologic subtype of endometrial and ovarian
cancers. Identification ofmutESR1 in up to 5% of endometrioid endome-
trial cancers is higher than previously reported (1.8%) [15]. Theutively active ESR1mutations in gynecologicmalignancies and clinical
, https://doi.org/10.1016/j.ygyno.2019.04.010
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treatment cases in the current dataset. Another endocrine-sensitive his-
tologic subtype, ESS, also exhibited a higher frequency ofmutESR1 than
its counterpart, LMS, however this was statistically significant in only
one dataset. Four cases exhibited two mutESR1 consistent with reports
of heterogeneity and polyclonality of mutESR1 in breast cancer [30].
The frequency of ESR1 amplifications in the current dataset, specifically
in the endometrial cancer cohort, is much lower than previously re-
ported [11–13]. The clinical relevance of ESR1 amplifications is still
unknown.
Endocrine therapy is preferentially used in low-grade gynecologic
malignancies. WhethermutESR1 are enriched in low-grade gynecologic
malignancies could not be determined because of the limited informa-
tion regarding tumor grade in the current study. However,mutESR1 ap-
pear to be enriched in histologic subtypes likely to have a higher
proportion of low-grade cases (i.e. endometrioid vs serous histology),
supporting the hypothesis. Further studies comparing the prevalence
of mutESR1 in high-grade and low-grade subtypes are needed. Never-
theless, these variants aremore likely to be clinically relevant in the sub-
set of tumors for which endocrine therapy is commonly utilized.
In breast cancer,mutESR1have been demonstrated to arise primarily
as a resistance mechanism to estrogen deprivation therapy resulting in
ligand-independent ERα signaling. The current study is limited by the
lack of information regarding prior treatment history from the majority
of patientswhose tumors underwent CGP. Thus it is impossible to deter-
mine whethermutESR1 emerge in gynecologic malignancies as a result
of exposure to endocrine therapy. However, at least three of the clinical
cases support the hypothesis that these mutations are selected for or
emerge as resistance mechanisms to AI therapy. This is consistent
with a recent case report of a patient with low-grade serous cancer
who was found to have a Y537S mutation in a metastatic lesion that
progressed after treatmentwith AI [31]. Interestingly,mutESR1 in breast
cancer appear more likely to develop after AI therapy in the metastatic
versus adjuvant treatment setting [32,33]. In a recent study of adjuvant
AI for low-grade serous ovarian cancer, no mutESR1 were identified in
the small proportion of patients who developed recurrent disease
[34]. Thus, mutESR1 may be more likely to develop in patients treated
with AIs for metastatic disease.
Conversely, three cases (Patients B, C and F) had no knownhistory of
endocrine therapy prior to identification of mutESR1. For Patient B, the
mutation was present in tumor at diagnosis, suggesting that the muta-
tion arose de novo and possibly played a role in the pathogenesis of
the tumor. Similarly, the mutESR1 identified in the TCGA cases were
from samples collected at the time of diagnosis. However, whether pa-
tients may have had prior exposure to anti-estrogens for treatment of
a separatemalignancy, such as breast cancer is not known. Nonetheless,
these mutations may develop independent of AI exposure and result in
intrinsic resistance to estrogen-deprivation therapies.
Because of the constitutive activity conferred by the mutation, tu-
mors with mutESR1 are unlikely to respond to AI therapy. The in vitro
studies support prior reports that higher doses of anti-estrogens are re-
quired to inhibit mutant ERα [1,8]. However, mutESR1 breast cancers
can respond to tamoxifen and fulvestrant supporting that efficacious
doses can be achieved clinically [2,4]. For Patient C, early identification
of the mutation has led to long-term clinical benefit with fulvestrant,
extending past 52 months at the time of submission of this manuscript.
Others also received clinical benefit, though this was not universal.
Overall, SERM/SERD therapy has the potential to provide benefit despite
the presence of a mutESR1.
What accounts for the variable differences in benefit among the clin-
ical cases ofmutESR1 is unknown.Differencesmay be due to 1. the use of
hormone therapy in a later phase of the disease course after develop-
ment of multiple adaptive/resistance mechanisms; 2. the influence of
co-occurring mutations; or 3. the specific mutESR1 present within
each tumor (e.g. Y537N vs Y537S). Supporting the third hypothesis,
the transcriptional data demonstrated that the efficacy of inhibition ofPlease cite this article as: S.L. Gaillard, K.J. Andreano, L.M. Gay, et al., Constit
response to estrogen-receptor directed therapies..., Gynecologic OncologyERα transcriptional activity with various SERMs/SERDS differs by indi-
vidual mutation. This is similar to the findings of other groups [5,35]
who showed differences in response to SERMs/SERDs between the
Y537S and D538G mutations. The current data shows that different
amino acid substitutions at the same site (Y537C vs Y537N vs Y537S)
also exhibit different IC50 to individual drugs. Furthermore, exposure
(Cmax) of some agents exceeds the IC90 of some, but not all, mutated re-
ceptors. It is important to recognize the limitations of this data: nuances
in transcriptional response in vitro may not translate to clinical efficacy
given the complexities of tumor proliferative signals and individual pa-
tient pharmacokinetic and pharmacodynamic considerations.
The finding ofmutESR1 in gynecologic malignancies has several im-
portant clinical implications. First,mutESR1 may arise de novo in gyne-
cologic malignancies in the absence of prior exposure to endocrine
therapy. Endocrine therapy, especially AIs, may increase the prevalence
of these mutations. Thus, traditionally endocrine-responsive gyneco-
logic malignancies should be assessed for these mutations. This may
be especially important for tumors that develop resistance or are refrac-
tory to endocrine therapy. Second, the functional and clinical data sup-
ports the use of alternative endocrine therapy, namely SERMs or SERDs,
in some patients with mutESR1 gynecologic malignancies. Thus, the
identification of amutESR1 does not preclude further treatmentwith se-
lected endocrine therapy, though relative response may be affected by
the individual mutation present. Given the low frequency of these mu-
tations in gynecologic malignancies, a large scale effort will be required
to delineate the prevalence ofmutESR1 across gynecologicmalignancies
and conditions under which they arise, with an emphasis on malignan-
cies considered for treatment with endocrine therapies. The recent de-
velopment of technology that can be used to evaluate mutation status
in plasma circulating tumor DNAmay be useful to non-invasively mon-
itor tumormutation status over time and in response to treatment [36].
This approach has identified greater heterogeneity and polyclonality in
the development of mutESR1 than had been appreciated with tissue
evaluation from individual mutation sites [2,30,36]. Finally, prospective
studies using ESR1 mutation status to direct endocrine therapy should
be undertaken to understand how these mutations may be used to
guide therapeutic decision making and personalize care for patients
with gynecologic malignancies.4. Materials and methods
4.1. Comprehensive genomic profiling
Comprehensive next generation sequencing-based genomic profil-
ing (CGP)was performed for 9645 cases of gynecologicmalignancies in-
volving the ovary, fallopian tube, uterus, cervix, placenta, vulva, or
vagina during the course of routine clinical care. Approval for this
study, including a waiver of informed consent and HIPAA waiver of au-
thorization, was obtained from the Western Institutional Review Board
(Protocol No. 20152817). The pathologic diagnosis of each case was
confirmed on routine hematoxylin and eosin (H&E) stained slides and
all samples forwarded for DNA extraction contained a minimum of
20% tumor nuclear area. From each sample, ≥50 ng DNA was extracted
from 40 μm of tumor samples provided as formalin-fixed, paraffin-
embedded (FFPE) tissue blocks.
The sequencingmethods used for CGP have been described in detail
elsewhere [37,38]. Sample processing and sequencing analysis was per-
formed in a Clinical Laboratory Improvement Amendments (CLIA)- and
College of American Pathologists (CAP)-accredited laboratory (Founda-
tion Medicine). Samples were assayed using adaptor-ligation and hy-
brid capture (Agilent SureSelect custom kit) next-generation
sequencing (FoundationOne®); genes assayed by version are listed in
Tables S6–9. Sequencing of captured libraries was performed using
Illumina HiSeq technology to a mean exon coverage depth of N500×,
and resultant sequences were analyzed as previously describedutively active ESR1mutations in gynecologicmalignancies and clinical
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viously reported [37,38].
4.2. Identification of ESR1 mutations in public databases
The cBioPortal [22,23] was used to access ESR1 mutation data from
the cervical TCGA [21], endometrial TCGA [20], ovarian TCGA [19], uter-
ine carcinosarcoma [17], and AACR Project GENIE datasets [18]. COSMIC
(cancer.sanger.ac.uk) [24] was used to identify an additional sample
with an ESR1 mutation from an ovarian cohort [16].
4.3. Clinical evaluation of gynecologic malignancies with mutESR1
Three cases were identified during review of medical records under
an Institutional Review Board protocol (with waiver of informed con-
sent and a HIPAA waver of authorization) at the Duke University Medi-
cal Center aimed at evaluating the utility of evaluation of ER in the
course of routine clinical care of patients with low-grade ovarian or en-
dometrial cancers treated at Duke University between January 1, 2000
and June 30, 2016. The other three cases were identified by searching
the Clearity FoundationOvarian Cancer Data Repository, which contains
clinical histories and tumor molecular profiling data collected with in-
formed patient consent under a Western Institutional Review Board-
approved protocol. Two cases from Mayo clinic were deemed exempt
by the IRB. Demographic, tumor characteristics, treatment and response
data were extracted for all cases.
4.4. Site-directed mutagenesis
Exsitemutagenesis was performed using the corresponding primers
in Table S10 on a pENTR2B ERαWT construct using Pfu-ultra Taq poly-
merase and primers were PNK phosphorylated. Following PCR amplifi-
cation, products were digested with DpnI at 37 °C for 1 h, followed by
overnight ligation at 16 °C. Ligated products were transformed into
DH5α bacterial cells and grown on kanamycin-resistant plates. The
pENTR clones were verified by sequencing and then swapped into the
pcDNA-DEST vector using the Gateway system (Invitrogen) for expres-
sion analysis.
4.5. Reporter gene assay
The following anti-estrogens were obtained through commercially
available sources: 17β-estradiol and 4-hydroxytamoxifen (Sigma-Al-
drich), ICI 182,780 and raloxifene (Tocris), bazedoxifene and
lasofoxifene (MedChem Express). GW7604 was synthesized by the
Duke Small Molecule Synthesis Facility. CAOV2 cells were co-
transfected with the 7X-ERE-TK luciferase reporter gene [39] and ex-
pression constructs for either wild-type or mutant receptors using
Fugene transfection reagent (Promega). pCMV-B-gal was used as a con-
trol for transfection efficiency and pcDNA was added for a final DNA
concentration of 75 ng per triplicate group. Cells were treatedwith indi-
cated ligand 5 h post-transfection. Following 24 h of treatment, cells
were lysed and the luciferase and β-gal assays were performed as de-
scribed previously [40]. Quantification was performed using the Fusion
α -FP HT plate reader (PerkinElmer Life Sciences).
4.6. Statistics
Data was analyzed using GraphPad Prism. p values for the compari-
son of mutESR1 frequency by primary site and histologic subtypes was
performed using Fisher's exact test. Dose-response curves for the tran-
scriptional assays were determined by log(inhibitor) vs. response
(three parameters). p values for comparison of the constitutive activity
of the mutations were performed using an unpaired t-test.
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